Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels - PubMed (original) (raw)
Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels
N N Lermontova et al. Bull Exp Biol Med. 2001 Nov.
Abstract
Dimebon, a Russian-made drug, inhibited toxic effects of beta -amyloid on cultured neurons. Excessive accumulation of beta-amyloid in the brain is characteristic of Alzheimer dementias. Antialzheimer preparations tacrine and dimebon improve survival of cerebellar granule cells during long-term incubation with Abeta25-35, the neurotoxic fragment of beta-amyloid. Both preparations can block potential-dependent Ca(2+) entry into neurons by about 20%, which is explained by their selective action on L-type Ca(2+) channels. It was assumed that the neuroprotective effect of dimebon and tacrine against Abeta25-35 partially depends on inhibition of potential-dependent Ca(2+) entry.
Similar articles
- Bis(7)-tacrine attenuates beta amyloid-induced neuronal apoptosis by regulating L-type calcium channels.
Fu H, Li W, Lao Y, Luo J, Lee NT, Kan KK, Tsang HW, Tsim KW, Pang Y, Li Z, Chang DC, Li M, Han Y. Fu H, et al. J Neurochem. 2006 Sep;98(5):1400-10. doi: 10.1111/j.1471-4159.2006.03960.x. Epub 2006 Jun 12. J Neurochem. 2006. PMID: 16771827 - Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer.
Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V, Grigorieva I, Ivanov Y, Sablin S, Zefirov N. Bachurin S, et al. Ann N Y Acad Sci. 2001 Jun;939:425-35. doi: 10.1111/j.1749-6632.2001.tb03654.x. Ann N Y Acad Sci. 2001. PMID: 11462798 Clinical Trial. - Huperzine A and tacrine attenuate beta-amyloid peptide-induced oxidative injury.
Xiao XQ, Wang R, Tang XC. Xiao XQ, et al. J Neurosci Res. 2000 Sep 1;61(5):564-9. doi: 10.1002/1097-4547(20000901)61:5<564::AID-JNR11>3.0.CO;2-X. J Neurosci Res. 2000. PMID: 10956426 - Recent Developments on Multi-Target-Directed Tacrines for Alzheimer's Disease. I. The Pyranotacrines.
Romero A, Marco-Contelles J. Romero A, et al. Curr Top Med Chem. 2017;17(31):3328-3335. doi: 10.2174/1568026618666180112155639. Curr Top Med Chem. 2017. PMID: 29332586 Review. - Tacrines as Therapeutic Agents for Alzheimer's Disease. IV. The Tacripyrines and Related Annulated Tacrines.
Bartolini M, Marco-Contelles J. Bartolini M, et al. Chem Rec. 2019 May;19(5):927-937. doi: 10.1002/tcr.201800155. Epub 2018 Nov 29. Chem Rec. 2019. PMID: 30489012 Review.
Cited by
- An update on treatment and prevention strategies for Alzheimer's disease.
Neugroschl J, Sano M. Neugroschl J, et al. Curr Neurol Neurosci Rep. 2009 Sep;9(5):368-76. doi: 10.1007/s11910-009-0054-1. Curr Neurol Neurosci Rep. 2009. PMID: 19664366 Free PMC article. Review. - Current treatment and recent clinical research in Alzheimer's disease.
Neugroschl J, Sano M. Neugroschl J, et al. Mt Sinai J Med. 2010 Jan-Feb;77(1):3-16. doi: 10.1002/msj.20165. Mt Sinai J Med. 2010. PMID: 20101716 Free PMC article. Review. - The Effects of Latrepirdine on Amyloid-β Aggregation and Toxicity.
Porter T, Bharadwaj P, Groth D, Paxman A, Laws SM, Martins RN, Verdile G. Porter T, et al. J Alzheimers Dis. 2016;50(3):895-905. doi: 10.3233/JAD-150790. J Alzheimers Dis. 2016. PMID: 26836170 Free PMC article. - Novel Sites of Neuroprotective Action of Dimebon (Latrepirdine).
Ustyugov A, Shevtsova E, Bachurin S. Ustyugov A, et al. Mol Neurobiol. 2015 Oct;52(2):970-8. doi: 10.1007/s12035-015-9249-4. Epub 2015 Jun 30. Mol Neurobiol. 2015. PMID: 26123670 Review. - Translatability scoring in drug development: eight case studies.
Wendler A, Wehling M. Wendler A, et al. J Transl Med. 2012 Mar 7;10:39. doi: 10.1186/1479-5876-10-39. J Transl Med. 2012. PMID: 22397594 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous